Incidence and outcome of vascular liver disease
Vascular liver diseases represent rare diseases that may occur with or without intrinsic parenchymal liver disease: Portal vein thrombosis (PVT), non-cirrhotic portal hypertension (NCPH), sinusoidal obstruction syndrome (SOS), Budd-Chiari syndrome (BCS), hereditary hemorrhagic teleangiectasia (HHT) and cirrhosis cardiaque. These diseases are commonly associated with prothrombotic conditions and cause significant morbidity and mortality explaining the need for optimal diagnostic and therapeutic management. Temporary or long-term anticoagulation is often necessary in these patients. However, anticoagulant treatment may be complicated in this population due to abnormalities in the hemostatic balance associated with liver disease. Furthermore, effects of anticoagulation on hepatic function and clinical outcomes remain to be established. The aims of the doctoral thesis project are to evaluate (i) the prevalence and potential risk factors for vascular liver diseases in patients with and without underlying chronic liver disease, (ii) the association with hemostatic dysbalance, and (iii) to describe the effects of anticoagulant treatment.
Methods and Skills:
Scheiner B, Lindner G, Reiberger T, Schneeweiss B, Trauner M, Zauner C, Funk GC. Acid-base disorders in liver disease. J Hepatol 67: 1062-1073, 2017
Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 52: 1008-1015, 2017
Scheiner B, Schwabl P, Steiner S, Bucsics T, Chromy D, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. Medicine (Baltimore) 95: e4061, 2016
Scheiner B, Mandorfer M, Schwabl P, Payer BA, Bucsics T, Bota S, Aichelburg MC, Grabmeier-Pfistershammer K, Stättermayer A, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS One 10: e0143429, 2015